Fludarabine Clinical Trials
254 recruitingDrug
Phase 1167Phase 2129Phase 312Early Phase 19Not Applicable4
Showing 1–20 of 254 trials
Recruiting
Phase 1Phase 2
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Breast CancerPancreatic CancerOvarian Cancer+2 more
National Cancer Institute (NCI)124 enrolled1 locationNCT02830724
Recruiting
Phase 1Phase 2
Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
Acute Lymphoblastic LeukemiaSmall Lymphocytic LymphomaLymphoblastic Lymphoma+4 more
National Cancer Institute (NCI)132 enrolled1 locationNCT06364423
Recruiting
Phase 3
Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy
Relapsed or Refractory Large B-cell Lymphoma
Kite, A Gilead Company550 enrolled10 locationsNCT07479797
Recruiting
Phase 1Phase 2
Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant
Hematopoietic and Lymphoid System Neoplasm
M.D. Anderson Cancer Center25 enrolled1 locationNCT04022239
Recruiting
Phase 1
Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center40 enrolled1 locationNCT07564232
Recruiting
Phase 1
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Refractory Autoimmune Diseases
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company125 enrolled28 locationsNCT07115745
Recruiting
Phase 1
GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
Triple-Negative Breast CancerRenal Cell CarcinomaAlveolar Soft Part Sarcoma
Canadian Cancer Trials Group30 enrolled2 locationsNCT07297667
Recruiting
Phase 1Phase 2
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
Hematologic Neoplasms
National Cancer Institute (NCI)430 enrolled1 locationNCT05327023
Recruiting
Phase 2
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Acute Myeloid LeukemiaMyelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic Therapy+2 more
National Cancer Institute (NCI)2,000 enrolled348 locationsNCT05564390
Recruiting
Phase 1
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
HIV InfectionRecurrent Non-Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma+12 more
AIDS Malignancy Consortium20 enrolled7 locationsNCT05077527
Recruiting
Phase 2
DALY II USA/ MB-CART2019.1 for DLBCL
Central Nervous System LymphomaTransformed LymphomaMantle Cell Lymphoma (MCL)+6 more
Miltenyi Biomedicine GmbH315 enrolled32 locationsNCT04792489
Recruiting
Phase 2
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome
Hematopoietic Stem Cell TransplantationImmunodeficiency
National Cancer Institute (NCI)54 enrolled1 locationNCT05027945
Recruiting
Phase 2
Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
Acute Myeloid LeukemiaMyelodysplastic Syndrome
OHSU Knight Cancer Institute102 enrolled1 locationNCT07228273
Recruiting
Phase 2
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Metastatic Breast CarcinomaMetastatic Ovarian CancerMetastatic Pancreatic Cancer+2 more
National Cancer Institute (NCI)332 enrolled1 locationNCT01174121
Recruiting
Phase 1Phase 2
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
Lupus Erythematosus, Systemic
AstraZeneca150 enrolled18 locationsNCT06897930
Recruiting
Phase 1
Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC
Head and Neck CancerRecurrentRelapse+1 more
UNC Lineberger Comprehensive Cancer Center33 enrolled1 locationNCT06096038
Recruiting
Not Applicable
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
HemoglobinopathiesImmunodeficienciesHematologic Disorders
Masonic Cancer Center, University of Minnesota30 enrolled1 locationNCT01666080
Recruiting
Phase 2
Allo HSCT Using RIC and PTCy for Hematological Diseases
Acute Myelogenous LeukemiaMyelodysplastic SyndromesLeukemia, Myeloid+15 more
Masonic Cancer Center, University of Minnesota56 enrolled1 locationNCT05805605
Recruiting
Phase 1Phase 2
T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias
Diamond-Blackfan AnemiaSickle Cell Anemiabeta thalassemia major
Paul Szabolcs5 enrolled1 locationNCT03653338
Recruiting
Phase 2
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
Multiple Myeloma
Janssen Research & Development, LLC60 enrolled17 locationsNCT07149857